NCT01118689

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Millennium Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety, tolerability, maximum tolerated dose and pharmacokinetics of MLN0128 in patients with Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Conditions

• Relapsed Multiple Myeloma
• Refractory Multiple Myeloma
• Waldenstrom Macroglobulinemia

Interventions

Type	Name	Description
DRUG	MLN0128	MLN0128 administered orally once daily for 28 days

Timeline

• Start date: 2010-11-01
• Primary completion: 2013-05-01
• Completion: 2013-07-01
• First posted: 2010-05-07
• Last updated: 2013-08-02

Locations

6 sites across 1 country: United States